Although FAK inhibition could abrogate the effects of NLG3, its therapeutic capacity is limited due to low permeability in infiltrative tumours such as DMGs [293]; as yet, PI3K/AKT/mTOR pathway inhibitors have not been explored for their potential to attenuate synaptic communication within this setting. The gene discussed is AKT1; the disease is neoplasm.